TEM — Tempus AI, Inc.
Is TEM overbought or oversold? Here is the current MarketMoodz read.
Tempus AI, Inc. (TEM) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Health Information Services) last closed at $76.63. The rating moved from Overbought to Oversold on October 1, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$76.63
- Last changeMoved from Overbought to Oversold on October 1, 2026
- SectorHealthcare
- IndustryHealth Information Services
See all oversold Healthcare stocks →
AI analysis
Tempus AI, Inc. (TEM) combines a large proprietary clinical and molecular dataset with AI tools and lab services that position it to capture revenue from precision oncology and pharma partnerships. Near term, the name is exposed to a cautious market tone, sector IPO weakness and payer/pricing pressures that can compress multiples and slow commercialization. Core upside depends on steady adoption of diagnostics and software, durable pharma collaborations, improving margins and clearer reimbursement pathways. Key risks include competitive dynamics, regulatory/privacy hurdles, and the possibility of capital needs if growth outpaces profitability. Monitoring upcoming commercial milestones, payer decisions, and partnership announcements will be critical to the stock's path over the next 1–3 months.
Key factors
- Proprietary clinical and molecular dataset that supports AI-driven diagnostic and decision-support products
- Diversified revenue mix from lab services, clinical assays, and pharma partnerships that can drive recurring revenue
- Growing demand for precision oncology and real‑world evidence from biopharma for trial design and drug development
- Operational leverage potential if utilization of the lab/diagnostics platform and software monetization scale
- Market sentiment vulnerability: healthcare IPO cooling and risk-off macro environment can compress multiples
- Strategic partnerships and payer coverage progress will materially influence near‑term commercial trajectory
Risks
- Valuation sensitive to market risk-off and sector-wide de‑risking (digital health & device IPO window cooling)
- Reimbursement and pricing pressure from Medicare negotiation dynamics and payer pushback on high-cost diagnostics
- Intense competition from other genomics, diagnostics and AI-health incumbents and startups (pricing and share erosion)
- Regulatory, data-privacy and compliance risks related to clinical data usage and diagnostic approvals
- Execution risk: translating research/AI models into consistent, reimbursable commercial products and margin improvement
- Capital intensity and cash-burn risk if revenue scaling or funding windows tighten, necessitating dilutive financing
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for TEM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.